NeoGenomics Sees Q3 Revenue Of About $209M; Reiterates FY2026 Revenue, Adjusted EBITDA Guidance, Expects To Raise Revenue Guidance Midpoint On Q3 Call

Benzinga Newsdesk www.benzinga.com Neutral 93.1%

Neg 0% Neu 93.1% Pos 0%

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001077183/000107718326000069/neo-20261005.htm

Comments

No comments yet. Be the first!